



Dynavax Technologies Corporation  
Investor Relations Department  
2929 Seventh Street  
Berkeley, CA 94710  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#)

#### NASDAQ: DVAX

|               |                             |
|---------------|-----------------------------|
| Last Trade:   | 18.80                       |
| Trade Time:   | 12:08 PM ET<br>Dec 11, 2017 |
| Change:       | 0.50<br>(+2.732%)           |
| Day Range     | 18.10 - 18.85               |
| 52-Week Range | 3.70 - 24.45                |
| Volume        | 313,685                     |

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Dynavax is a clinical-stage immunology company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax is developing product candidates for use in m... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Dec 5, 2017*  
[Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635\(c\)\(4\)](#)
- Nov 27, 2017*  
[Dynavax to Present at the Evercore ISI Biopharma Catalyst/Deep Dive Conference](#)
- Nov 9, 2017*  
[Dynavax Announces FDA Approval of HEPLISAV-B\(TM\) for Prevention of Hepatitis B in Adults](#)
- Nov 3, 2017*  
[Dynavax Reports Third Quarter 2017 Financial Results](#)
- Oct 19, 2017*  
[Dynavax Initiates Clinical Trial in Non-Small Cell Lung Cancer with a Novel Inhaled TLR9 Agonist in Combination with Anti-PD-1 Therapy](#)

## Financials [\[ View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 13, 2017*  
[Annual Report \(10-K\)](#)
- Jul 10, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Nov 3, 2017*  
[Quarterly Report \(10-Q\)](#)
- Aug 7, 2017*  
[Quarterly Report \(10-Q\)](#)
- May 8, 2017*  
[Quarterly Report \(10-Q\)](#)